Partnering for Innovation in Manufacturing & Supply

How are bio/pharma companies and their partners collaborating to resolve the difficult challenges that arise in development, manufacturing, and the supply chain? DCAT Member Companies are invited to apply to share fresh insights, best practices, and lessons learned at a DCAT Week program. Applications close January 13, 2025.

How are bio/pharma companies and their partners collaborating to resolve the difficult challenges that arise in development, manufacturing, and the supply chain? DCAT Member Companies are invited to apply to share fresh insights, best practices, and lessons learned at a DCAT Week program. Applications deadline extended and closes January 24, 2025.

By Patricia Van Arnum, Editorial Director, DCAT, pvanarnum@dcat.org

A solutions-based program at DCAT Week
Innovation is essential for achieving operational excellence and delivering value. A DCAT Week 2025 program, Partnering for Innovation in Manufacturing & Supply, will feature case studies on how bio/pharma companies and their partners have collaborated to resolve the hard challenges that arise in development, manufacturing, and the supply chain. Partner companies include CDMOs/CMOs, suppliers of raw materials or other inputs, technology services providers, or other companies, including other bio/pharma companies.

The 90-minute program will consist of three co-presentations (20 minutes each) between a bio/pharma company and partner company. It is a way to share fresh insights, best practices, and lessons learned to a well-informed business audience of senior to mid-level executives.

DCAT Member Companies are invited to submit applications by January 24, 2025, for consideration of their case study.  A task force of industry colleagues selected from DCAT volunteer committees and leadership will evaluate all applications and select three case studies providing the most useful, valuable, and innovative insight of utility and interest to DCAT Member Companies. Presentations will be due March 3, 2025. Further information, including the online application to apply, may be found here.

Topics of interest
The case studies may address a range of topics—but must reflect an innovative or better approach taken in manufacturing or supply. Potential topics can include:

  • New technologies in drug-substance and drug-product manufacturing or packaging;
  • Cost optimization and improved production economics;
  • Collaborative project management;
  • Increasing supply-chain performance, resiliency, or visibility;
  • Upgraded inventory management;
  • Collaborative demand and supply planning/forecasting;
  • Sustainability improvements: technology, manufacturing & metrics;
  • Digitalization to better performance, including regulatory compliance; or
  • Other innovation in manufacturing and supply.

The program provides a way to stand out among your peers in the industry by showing  resourceful and effective ways to advance manufacturing and supply. Further information, including the online application to apply, may be found here.

Recent Feature Articles

US, EU Detail Plan for Pharmaceutical Tariffs

By
The White House and European Commission have released further details on the recently agreed-to US-EU trade deal, including further details on tariffs on pharmaceuticals. What’s the bottom line for the pharma industry?

Big Pharma & US Manufacturing Investment

By
The White House released last week a list of major capital investments in the US for manufacturing, including from the pharmaceutical industry. A roundup of investments gaining attention and other moves thus far in 2025.

State of the State: AI in Procurement: Where Does It Stand?

By
The potential of AI to transform business functions, including procurement, is strong, but where does it actually stand? A recent analysis by the business and technology consulting firm, Gartner, provides a reality check for current and future adoption.

White House Takes Next Steps To Onshore Mfg to US & Stockpiling APIs

By
FDA is seeking public comment through October 8 on how the US government can facilitate the onshoring of pharma manufacturing to the US. Also, President Donald Trump issues an Executive Order for stockpiling essential medicines in the US.